ANG Lifesciences India Ltd.
Snapshot View

331.25 +15.75 ▲5.0%

02 August 2021, 04:00:00 P.M.
Volume: 59,200

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.anglifesciences.com
Financial Indicators
Market Cap 163.53 Cr.
Earnings per share (EPS) 13.56 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 23.27 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 66.67 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.73 Calculated using Price: 315.50
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 0.52 Cr. 5,183,315 Shares
FaceValue 10
Company Profile

ANG Lifesciences India was originally incorporated as ‘ANG Lifesciences India Private Limited’ on June 14, 2006 with the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh as a private limited Company under the Companies Act, 1956. On conversion into public limited Company the name of the Company was changed to ‘ANG Lifesciences India Limited’ pursuant to special resolution passed at the Extra Ordinary General Meeting held on January 18, 2010 and a fresh certificate of incorporation dated March 02, 2010 issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh. The company was further converted into private limited Company and the name of the Company was changed to ‘ANG Lifesciences India Private Limited’ pursuant to special resolution passed at the Extra Ordinary General Meeting held on August 31, 2010 and a fresh certificate of incorporation was issued by Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh dated September 22, 2010. Subsequently, on conversion into public limited Company the name of the company again changed to ‘ANG Lifesciences India Limited’ pursuant to special resolution passed at the Extra Ordinary General Meeting held on May 04, 2016 and a fresh certificate of incorporation dated May 18, 2016 issued by the Registrar of Companies, Chandigarh.

Business area of the Company

The company is ISO-9001:2008 certified and has the modern & sophisticated plant, equipments, technique and manpower. The planning and construction of plant has been done to conform to the regulatory requirements as per the norms of WHO G.M.P. and G.L.P. as per schedule-M (revised). They manufacture their products in compliance with GMP requirements. They have dedicated area, machinery, facilities and advanced equipments for manufacturing of B-Lactum & Non-B Lactum products as per GMP Norms. The production block provides appropriate personnel and material flow. As per GMP norms, all the production processes are documented and validated to establish the accuracy of the procedures and the control measures. The Company’s production capacity is 700 Lakhs Pcs per annum on per shift basis. Their products include sterile dry powder vials for Anti Biotics, Anti Ulcerant, Gluco corticoid and Anti inflammatory, Anti malarial and Anesthetic.

 Its customer list includes Wockhardt, DHS Maharashtra, Global Hospitals, Elder, Emcure, BPPI, Govt. of Haryana, Hetero Healthcare etc.

Major Events & Milestones:

  • 2006-07: Incorporation of the Company on June 14, 2006.
  • 2008-09: Commenced commercial production of the Company.
  • 2012-13: Robust jump in the turnover of the Company by 140% as compared to previous year.
  • 2013-14: Commenced their export sales, Government supplies and turnover increased by 112% as compared to previous year.
  • 2014-15: Commenced direct sale of medicines in PAN India covering hospitals, Doctors through stockists.
  • 2015-16: Company certified with WHO and GMP norms and continued to growth in the turnover.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.99%
1 Week
+27.58%
1 Month
+204.18%
3 Month
+165.00%
6 Month
+316.67%
1 Year
+699.16%
2 Year
+968.55%
5 Year
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -73.42 -2.70 7.74 13.86 41.97 46.06 24.29 21.75 19.25
Return on Capital Employed (%) -2.90 13.11 12.81 15.15 23.36 29.66 22.23 23.66 22.39
Return on Assets (%) -9.58 -0.32 0.84 1.59 5.40 6.86 6.48 7.58 6.97

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 2 2 3 3 5 7 23 29 35
Non Curr. Liab. 2 11 10 8 7 5 10 10 9
Curr. Liab. 13 8 13 15 24 34 35 42 51
Minority Int.
Equity & Liab. 18 21 25 26 35 47 68 81 94
Non Curr. Assets 12 11 9 9 9 9 21 21 21
Curr. Assets 6 10 16 17 26 38 47 60 73
Misc. Exp. not W/O
Total Assets 18 21 25 26 35 47 68 81 94

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 7 16 35 37 55 68 76 122 127
Other Income 0 0 0 0 0 0 1 0 0
Total Income 7 16 35 37 55 68 77 122 127
Total Expenditure -7 -14 -30 -34 -50 -61 -69 -110 -114
PBIDT 0 3 5 3 5 7 8 12 13
Interest -2 -2 -2 -2 -2 -2 -2 -3 -3
Depreciation -1 -1 -3 -1 -1 -1 -1 -1 -1
Taxation 0 0 0 0 -1 -1 -1 -2 -2
Exceptional Items
PAT -2 0 0 0 2 3 4 6 6

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 8 -8 4 3 2 5 1 7 5
Cash Fr. Inv. -2 -2 -2 -2 -3 -1 -13 -1 -2
Cash Fr. Finan. -5 10 -1 -1 2 -3 13 -4 -4
Net Change 0 0 0 0 1 0 1 3 -1
Cash & Cash Eqvt 0 1 1 0 1 1 1 4 4

Shareholding Pattern View Details

9 Qtrs 2017-08 (%) 2017-09 (%) 2018-03 (%) 2018-09 (%) 2019-03 (%) 2019-09 (%) 2020-03 (%) 2020-09 (%) 2021-03 (%)
Promoter 99.95 71.01 71.01 71.01 71.01 71.01 71.01 71.01 71.01
Public 0.05 28.99 28.99 28.99 28.99 28.99 28.99 28.99 28.99
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 25.29 25.29 25.29 25.29 25.29 67.54 42.25

Announcements View Details

Sat, 31 Jul 2021
Closure of Trading Window
In continuation to our earlier intimation dated July 30th 2021 for the meeting of Board of Directors of the Company scheduled to be held on Friday 6th August 2021 at 3:30 P.M. we would like to inform you that as per the SEBI (Prohibition of Insider Trading) Regulation 2015 as amended from time to time and the Companys Code of Conduct to regulate monitor and report the trading of equity shares the Trading Window for dealing in the securities of the company by the designated persons and their immediate relatives of the company has already been closed from 30th July 2021 and shall remain closed till 48 hours from the closure of the Board Meeting.

Please take the same on your record.
Fri, 30 Jul 2021
Corporate Action-Board to consider Bonus Issue
Pursuant to the Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 It is hereby informed you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday August 06th 2021 at 03:30 P.M. at the Registered Office of the Company situated at Darbara Complex SCO-113 District Shopping Centre B Block Ranjit Avenue Amritsar-143001 inter alia transact the following business:
1. To consider and approve Increase in Authorised Share Capital of the Company.
2. To consider and approve the Issue of Bonus Shares.
3. To consider and approve the Migration of the Company from BSE SME Platform to Main Board of BSE Limited.
4. Any other business that may be necessary with the permission of Chairman.

Please take the same on your record.
Fri, 30 Jul 2021
Board Meeting Intimation for Intimation Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulation 2015
ANG Lifesciences India Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 inter alia to consider and approve Pursuant to the Regulation 29 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015 It is hereby informed you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday August 06th 2021 at 03:30 P.M. at the Registered Office of the Company situated at Darbara Complex SCO-113 District Shopping Centre B Block Ranjit Avenue Amritsar-143001 inter alia transact the following business:
1. To consider and approve Increase in Authorised Share Capital of the Company.
2. To consider and approve the Issue of Bonus Shares.
3. To consider and approve the Migration of the Company from BSE SME Platform to Main Board of BSE Limited.
4. Any other business that may be necessary with the permission of Chairman.

Please take the same on your record.

Technical Scans View Details

Fri, 30 Jul 2021
High Delivery Percentage High Delivery Percentage
Close Crossing 52 Week High Close Crossing 52 Week High
Opening at High Opening at High
Opening at Low Opening at Low
Closing Above Previous High Closing Above Previous High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.45 +0.1%
Divi's Laboratories Ltd. 129,702.64 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,701.80 -0.2%
Cipla Ltd. 74,235.31 921.80 +0.2%
Cadila Healthcare Ltd. 59,986.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,049.00 +0.4%
Aurobindo Pharma Ltd. 53,701.27 918.00 +0.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 30.87 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 918.00 +0.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,701.80 -0.2%
Cipla Ltd. Consolidated 2021-03 4.05 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 918.00 +0.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 918.00 +0.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 918.00 +0.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 918.00 +0.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 918.00 +0.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.45 +0.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,928.00 +0.5%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,701.80 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 921.80 +0.2%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 591.70 +1.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,049.00 +0.4%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 918.00 +0.1%